#OP0205 #EULAR2026: 🌞SUNSTAR head-to-head trial compared SC TOC vs Abatacept after failure of 1-2 b/tsDMARDs in RA. Primary CDAI endpoint was not met, but composite response and treatment persistence favoured tocilizumab. @RheumNow https://t.co/UepvKcbiNJ

Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA 169 pts 12mo -IL-17i no MACE reported -CRP reduced 4.8 → 2.9 mg/L, p<0.001 -79% systemic inflammatory response -Lipids stable (LDL, TG, TC) 12mo follow up is probably too short though #POS0375 #EULAR2026 https://t.co/u6cvB5YYGq

#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY

Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs 12mo 150 pts -CD4+ gE-T-cell response peaks mo 3 -Response seen in axSpA + GCA, but not RA -25% of patients no CMI increase after vaccination Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj

Frailty as a long term outcome in RA Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs. -10y: 30.6% vs 19.1% -20y: 53.8% vs 35.3% -Stronger in recent RA (HR 2.38) Driven by age, smoking, comorbidity, steroids/biologics not RF/CCP. Preventive interventions needed https://t.co/pcJrE73G5O

TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX

Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya

Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR

#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi